261 related articles for article (PubMed ID: 30009128)
21. Amyloid-β, Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder.
Elias A; Cummins T; Lamb F; Tyrrell R; Dore V; Williams R; Rosenfeld JV; Hopwood M; Villemagne VL; Rowe CC
J Alzheimers Dis; 2020; 73(1):163-173. PubMed ID: 31771068
[TBL] [Abstract][Full Text] [Related]
22. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
23. β-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study.
Hicks AJ; Ponsford JL; Spitz G; Dore V; Krishnadas N; Roberts C; Rowe CC
Neurology; 2022 Sep; 99(11):e1131-e1141. PubMed ID: 36096678
[TBL] [Abstract][Full Text] [Related]
24. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
25. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of tau deposition using
Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
[TBL] [Abstract][Full Text] [Related]
27. Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report.
Weiner MW; Harvey D; Hayes J; Landau SM; Aisen PS; Petersen RC; Tosun D; Veitch DP; Jack CR; Decarli C; Saykin AJ; Grafman J; Neylan TC;
Alzheimers Dement (N Y); 2017 Jun; 3(2):177-188. PubMed ID: 28758146
[TBL] [Abstract][Full Text] [Related]
28. Clusters of Low (18)F-Fluorodeoxyglucose Uptake Voxels in Combat Veterans with Traumatic Brain Injury and Post-Traumatic Stress Disorder.
Buchsbaum MS; Simmons AN; DeCastro A; Farid N; Matthews SC
J Neurotrauma; 2015 Nov; 32(22):1736-50. PubMed ID: 25915799
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
30. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
31. Evidence of increased brain amyloid in severe TBI survivors at 1, 12, and 24 months after injury: report of 2 cases.
Gatson JW; Stebbins C; Mathews D; Harris TS; Madden C; Batjer H; Diaz-Arrastia R; Minei JP
J Neurosurg; 2016 Jun; 124(6):1646-53. PubMed ID: 26613169
[TBL] [Abstract][Full Text] [Related]
32. Towards the Integrative Theory of Alzheimer's Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis.
Molkov YI; Zaretskaia MV; Zaretsky DV
Curr Alzheimer Res; 2023; 20(6):440-452. PubMed ID: 37605411
[TBL] [Abstract][Full Text] [Related]
33. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
34. Escalation of Tau Accumulation after a Traumatic Brain Injury: Findings from Positron Emission Tomography.
Mohamed AZ; Cumming P; Nasrallah FA; Alzheimer's Disease Neuroimaging Initiative
Brain Sci; 2022 Jul; 12(7):. PubMed ID: 35884683
[TBL] [Abstract][Full Text] [Related]
35. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
36. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
[TBL] [Abstract][Full Text] [Related]
37. Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury.
Abu Hamdeh S; Waara ER; Möller C; Söderberg L; Basun H; Alafuzoff I; Hillered L; Lannfelt L; Ingelsson M; Marklund N
Brain Pathol; 2018 Jul; 28(4):451-462. PubMed ID: 28557010
[TBL] [Abstract][Full Text] [Related]
38. Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts.
Li TR; Dong QY; Jiang XY; Kang GX; Li X; Xie YY; Jiang JH; Han Y;
Neuroimage Clin; 2022; 33():102900. PubMed ID: 34864286
[TBL] [Abstract][Full Text] [Related]
39. PET Amyloid and Tau Status Are Differently Affected by Patient Features.
Tan MS; Yang YX; Wang HF; Xu W; Tan CC; Zuo CT; Dong Q; Tan L; Yu JT;
J Alzheimers Dis; 2020; 78(3):1129-1136. PubMed ID: 33104024
[TBL] [Abstract][Full Text] [Related]
40. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
